Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-231-8 | CAS number: 12136-78-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A 28-day repeated dose toxicity study by oral route is available for molybdenum disilicide. No adverse effects were observed up to the highest tested dose. The NOAEL is > 1000 mg/kg bw/day.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral, other
- Remarks:
- Sub-Acute Oral Toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- other: Wistar (RccHan: WIST) rat
- Sex:
- not specified
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% w/v aqueous carboxy methyl cellulose (CMC)
- Duration of treatment / exposure:
- Treatment period: 28 days; Recovery period: 14 days
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- G1 (vehicle control)
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- G5 (vehicle control recovery)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Remarks:
- G2 (low dose)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- G3 (mid dose)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- G4 (high dose)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- G6 (high dose recovery)
- No. of animals per sex per dose:
- 5 rats/sex/group
- Control animals:
- yes
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No morbidity or abnormal clinical sign was observed in any group, throughout study period.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality was observed in any group, throughout study period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No significant change was observed in the mean body weight and mean body weight change in rats from treatment groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No significant change was observed in the mean food consumption in rats from treatment groups.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmological examination did not reveal any abnormality in any rat.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Test item treatment did not lead to any adverse effect in clinical pathology (haematology, coagulation, clinical chemistry and urinalysis) parameters.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Test item treatment did not lead to any adverse effect in clinical pathology (haematology, coagulation, clinical chemistry and urinalysis) parameters.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Test item treatment did not lead to any adverse effect in clinical pathology (haematology, coagulation, clinical chemistry and urinalysis) parameters.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No treatment related change was observed in neurobehavioural observations and functional observational battery performed in rats from treatment groups
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Test item treatment did not lead to any alteration on organ and relative organ weights.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- External and internal examination of terminally and recovery sacrificed rats of either sex across various groups (G1 to G6) did not reveal any abnormality.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- The microscopic examination did not reveal any significant alteration related to the test item treatment.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- not specified
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed
- Critical effects observed:
- no
- Conclusions:
- Sub-acute oral NOAEL in rats: > 1000 mg/kg bw/day.
- Executive summary:
The objective of this study was to evaluate the potential toxicity of molybdenum disilicide in Wistar rats, following daily administration through oral gavage for 28 consicutive days. Results of this study provide information on any systemic adverse effect, target organ, and an estimation of the No Observed Adverse Effect Level (NOAEL) and/or No Observed Effect Level (NOEL).
Based on results of this study, it is concluded that molybdenum disilicide did not produce any toxicity or adverse effect up to the dose level of 1000 mg/kg b. wt./day after the 28 days repeated oral administration through gavage in Wistar rats. The NOAEL (No Observed Adverse Effect Level) for molybdenum disilicide, in both male and female rats, was found to be 1000 mg/kg b. wt./day, under conditions and procedures followed in this study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
According to the results of the subacute oral toxicity study, no calssification for specific target organ toxicity after repeated exposure is deemed necessary.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.